Clinical studies of CS-866, the newest angiotensin II receptor antagonist

The American Journal of Cardiology
J Neutel

Abstract

Angiotensin II receptor blockers have shown widespread efficacy as antihypertensive medications. These agents bind selectively to angiotensin II type 1 (AT(1)) receptors, specifically blocking the renin-angiotensin system at the last step in its cascade. CS-866 is the most recently introduced drug in this class. This article presents integrated safety and efficacy data from 7 randomized, double-blind, placebo-controlled, parallel group studies in which once-daily CS-866 monotherapy was used in the treatment of patients with essential hypertension (sitting diastolic blood pressure > or =100 mm Hg and < or =115 mm Hg). Data from a total of 2,145 CS-866-treated patients were included in the efficacy analysis. Safety data were available from 2,540 CS-866-treated patients, with a cumulative exposure of 5,888 patient-months. The antihypertensive efficacy of the drug was assessed using both cuff blood pressure measurements and 24-hour ambulatory blood pressure monitoring. The data show that CS-866 is effective and safe for the treatment of hypertension. Dose-dependent reductions in both diastolic and systolic blood pressures occurred within 1 week of initiating treatment, and the response was almost maximal within 2 weeks. There was n...Continue Reading

References

May 4, 2001·The American Journal of Cardiology·B Williams
May 4, 2001·The American Journal of Cardiology·D E Vaughan

❮ Previous
Next ❯

Citations

Feb 28, 2007·Vascular Health and Risk Management·Hans R Brunner
Feb 28, 2007·Vascular Health and Risk Management·Mark Greathouse
Sep 17, 2009·Vascular Health and Risk Management·Vivencio BarriosMichael Böhm
Jul 1, 2008·Future Cardiology·Christoph Schindler, Carlos M Ferrario
Aug 20, 2009·Expert Opinion on Drug Metabolism & Toxicology·Maurizio DestroFrancesca Cagnoni
Apr 10, 2004·The Journal of Clinical Hypertension·Joel M NeutelHarvey N Masonson
Jan 5, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·S Ichikawa, Y Takayama
Jan 6, 2009·The Journal of Clinical Hypertension·Ikuo SaitoMasahiro Komiya
Oct 15, 2013·Gastrointestinal Endoscopy·Jennifer SeminerioAatur D Singhi
Aug 19, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Devender KodatiNarsimhareddy Yellu
Mar 20, 2009·Expert Review of Cardiovascular Therapy·Henry A Punzi
Sep 1, 2008·Expert Review of Clinical Pharmacology·Mark Greathouse
Mar 5, 2017·Cardiology and Therapy·Xiaoshen ZhangMichael R Hamblin
Mar 1, 2005·Seminars in Cardiothoracic and Vascular Anesthesia·Linda Shore-Lesserson
Aug 22, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toshihiko IshimitsuHiroaki Matsuoka
Oct 7, 2004·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshio Sada, Makoto Mizuno
Mar 15, 2014·Electrolyte & Blood Pressure : E & BP·Da-Rae KimChun-Gyoo Ihm
Dec 14, 2006·Clinical Drug Investigation·Reinhold KreutzMatthias Huber
Nov 27, 2004·Blood Pressure Monitoring·Thomas MengdenHans Vetter
Dec 31, 2002·The Annals of Pharmacotherapy·Stephanie F Gardner, Amy M Franks
Oct 18, 2002·American Journal of Hypertension·Lennart Hansson
Mar 17, 2007·Chronobiology International·Michael H SmolenskyFrancesco Portaluppi
May 8, 2010·Expert Opinion on Pharmacotherapy·Vivencio Barrios, Carlos Escobar
Dec 30, 2011·Clinical Pharmacology and Therapeutics·D E SalazarT J Carrothers
Dec 14, 2004·Cardiovascular Drug Reviews·Kazunori Yoshida, Masahiro Kohzuki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.